Dangerous snow and ice, along with FSHD symptoms, made it impossible for columnist Robin Stemple to leave his home for two weeks.

A Phase 3 clinical trial testing SGT-003, a gene therapy candidate for Duchenne muscular dystrophy (DMD), will start dosing ...

When faced with a bad moment or adverse event, columnist Patrick Moeschen says it helps to remember the rule of 10.

Sudden illnesses and recent losses have caused columnist Betty Vertin to reflect on the things worth worrying about, and ...

Three years after Elevidys treatment, boys with DMD show sustained motor function compared with expected disease progression.

After realizing that his friends were eager to learn about his MD, columnist Patrick Moeschen became more passionate about ...

Columnist Betty Vertin is grateful she's been able to manage cold and flu season at home for her three sons with DMD, and her whole family.

Columnist Shalom Lim experienced a range of emotions while watching other actors perform a play he wrote about muscular dystrophy.

The FDA has granted fast track designation to Dyscorban, Cumberland's therapy candidate for heart problems in people with Duchenne MD.

A research collaboration led by the Muscular Dystrophy Association (MDA) aims to create a molecular map of human muscle regeneration, a project that could accelerate the development of muscle ...

CureDuchenne is a global leader in research, patient care and innovation for improving and extending the lives of those with Duchenne muscular dystrophy. CureDuchenne’s innovative venture philanthropy ...